A 12-Week, Phase 1, Multicenter, Double-Blind, Randomized, Dose Ranging, Forced Titration, Naproxen-Controlled, Parallel-Group, Pharmacodynamic Study, to Assess the Effects Different Doses of Naproxcinod and Naproxen on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension.

Trial Profile

A 12-Week, Phase 1, Multicenter, Double-Blind, Randomized, Dose Ranging, Forced Titration, Naproxen-Controlled, Parallel-Group, Pharmacodynamic Study, to Assess the Effects Different Doses of Naproxcinod and Naproxen on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2011

At a glance

  • Drugs Naproxcinod; Naproxen
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors NicOx
  • Most Recent Events

    • 06 May 2009 Results presented at ASH 2009.
    • 27 Jan 2009 Status changed from active, no longer recruiting to completed, as reported in clinicalTrials.gov record.
    • 04 Nov 2008 Results have been reported in a NicOx media release; further results will be presented at a leading cardiology conference in 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top